Vision, Integrity, Expertise
Soligenix, Inc. Soligenix, Inc. is a clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Monday, April 07, 2014Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
Wednesday, March 26, 2014Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
Tuesday, March 11, 2014Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.